Skip to content

EV / EBITDA at other companies

Pfizer logo
PfizerPFE
12.9×
Merck & Co. logo
Merck & Co.MRK
23.1×+11.7×
AbbVie logo
AbbVieABBV
19.8×
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
30.3×
Alkermes logo
AlkermesALKS
30.8×+18.8×
Organon logo
OrganonOGN
-1.0×

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.4B+9.7%
P/E3.5×
P/S4.1×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Calculated from Innoviva, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s EV / EBITDA?
Innoviva, Inc. (INVA) reported EV / EBITDA of 7.5× in Q1 2026.
How has Innoviva, Inc.'s EV / EBITDA changed year-over-year?
Innoviva, Inc.'s EV / EBITDA increased by 22.4% year-over-year, from 6.1× to 7.5×.
What is the long-term trend for Innoviva, Inc.'s EV / EBITDA?
Over 4 years (2020 to 2025), Innoviva, Inc.'s EV / EBITDA has grown at a 20.9% compound annual growth rate (CAGR), from 3× to 6.4×.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.